Safety of Gepants for Migraine

Migraine is a highly disabling condition with a great unmet need. Calcitonin gene-related peptide (CGRP) receptor targeting therapies are novel, migraine-specific options that have gained widespread use. Gepants are CGRP antagonists used for the acute (rimegepant, ubrogepant, zavegepant) and preventive treatment of migraine (rimegepant, atogepant). This real-world investigation was done to evaluate for rare or long-term adverse events (AEs) not evident in clinical trials.

A retrospective disproportionality analysis using the Food and Drug Administration Adverse Event Reporting System (FAERS) database aimed to detect adverse safety signals with gepants, focusing on organ and system involvement.